Health & Wellness

Canada’s drug regulator issues final positive review supporting public reimbursement of Leqembi® for early Alzheimer’s disease, marking a significant policy shift.

• Deal Sucker Team
• September 1, 2026

HUTCHMED announces SANOVO trial showing notable progression-free survival benefits with ORPATHYS® plus TAGRISSO® in lung cancer patients in China.

• Deal Sucker Team
• August 31, 2026

Hanmi Pharm has entered an exclusive licensing agreement with Genentech to develop and commercialize a novel obesity therapy, marking a significant step in obesity treatment.

• Deal Sucker Team
• August 24, 2026

Anbogen Therapeutics and The University of Tokyo have announced a collaborative research agreement to evaluate ABT-301 across multiple tumor types, aiming to accelerate clinical development.

• Deal Sucker Team
• August 24, 2026

Kura Oncology announced a new publication in Blood highlighting Ziftomenib’s unique binding profile and preclinical activity, marking a potential advancement in AML treatment.

• Deal Sucker Team
• August 10, 2026

HanchorBio partners with Taiwan Cancer Moonshot Project-NTU Subteam led by Professor Sung to advance cancer treatment research through strategic collaboration.

• Deal Sucker Team
• August 10, 2026

Insilico Medicine has announced ISM9077 as a preclinical candidate for ocular, inflammatory, and aging diseases, leveraging AI-driven drug discovery.

• Deal Sucker Team
• August 6, 2026

The Stork Foundation for Infertility has announced opening of grant applications for 2026 to help reduce the financial burden of IVF treatments.

• Deal Sucker Team
• August 1, 2026

CG Oncology announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology, highlighting potential advances in cancer treatment.

• Deal Sucker Team
• July 28, 2026

Akari Therapeutics CEO discusses how increasing industry demand for advanced antibody-drug conjugate payloads positions the company for growth in oncology.

• Deal Sucker Team
• July 22, 2026